Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

Average changes in (A) spontaneous AP firing rate, (B) ATP and (C) cAMP by decreasing CaMKII activity with KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L). by Yael Yaniv (162548)

Schematic diagram of the track and latch comparator (a) conventional track and latch comparator (b) small signal model of the comparator. by Labonnah Farzana Rahman (641767)

Subjects:

<i>Fgfr2^+/S252W</i> mice had shortened bone length and decreased bone mass compared with wild-type mice. by Peng Chen (6514)

“…<p>(A–F) X-ray analyses of femora, tibia and lumbar vertebrae from WT and MT mice at P5 (A, B), P10 (C, D) and P28 (E, F) revealed shorter bone length and lower bone density in mutant mice. …”

CPGF NPs decrease the growth kinetics of breast cancer cells. by Kirtee D. Wani (636463)

“…<p>(<b>A</b>) The NPs decreased the number of cells in MDAMB231 and MCF7, indicated by cell growth assay. …”

Mean decrease in accuracy (MDA) of top 15 urine metabolites. by Liam E. Broughton-Neiswanger (8447220)

Experimental features ranked with respect to their mean decrease in the Gini index. by Rajib Mukherjee (532424)

Relationship between the delta VE/VT ratio and the mean decrease in oxygen saturation during the run. by Eva Bernardi (3897652)

Decrease in the number of intestinal pDCs in <i>Enpp3</i>^<i>-/-</i> mice. by Yoki Furuta (3772735)

Comparison of W_max (A), the changes in V_E (B), and W_VT (C) among the three oxygen conditions. by Kazufumi Hisamoto (21416905)

Low oscillatory shar stress <i>Arf6</i> heterozygosity decreases Arf6 expression. by Venkateswara R. Gogulamudi (15447428)

The Mean Decreasing Gini OTU importance plot for the fecal samples. by Zaid Abdo (175649)